Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kadcyla Positioned For Wide Use In Metastatic Breast Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line HER-2 positive mBC, but labeling allows first-line treatment in a subset of patients at high risk.

You may also be interested in...



India’s Biocon Wins 1st Biosimilar Approval Of Herceptin; Will Launch Before March 2014

As the decks are cleared for an India launch of trastuzumab, Biocon and its global partner Mylan will be watched closely by both local and global competitors. The market impact in India will be most significant in terms of price, and it will test if Roche has played its cards right by aligning with local company Emcure.

Celltrion Files For Korea Approval Of Herceptin Biosimilar

Amid M&A talks and expectations for imminent European approval of a Remicade biosimilar, Celltrion becomes the first company to file for regulatory approval of a biosimilar of Roche’s blockbuster breast cancer therapy trastuzumab.

Roche’s Oncology Output Could Lead To Reimbursement Problems Down The Line

Roche posted solid 2012 results and development of new cancer drugs continues apace, forecasting further sales and profit gains in 2013 and beyond – as long as government insurers can handle the abundance.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel